
Indoco Remedies Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 2
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Domestic business growth: Confident of achieving 14%-16% growth in H2 FY24, driven by both seasonal products and sub-chronic therapies like stomatology and ophthalmics.
- Europe business: Maintaining guidance of Rs. 375-380 crores for FY24 with expectation of order normalization after recent overstocking issues.
- US business: Expect continued strong performance with sustainable profit share from products like Brinzolamide in Q3 and Q4.
- Emerging markets: Significant growth observed (71.6% rise in Q2 revenues), expected to continue.
- API business: Strong growth (95.6% increase in Q2), indicating robust volume expansion.
- Overall company outlook: Well-positioned with ongoing capacity expansions, new product launches, ANDA filings, and improved operational efficiencies to support volume and value growth.
See what Indoco Remedies management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The transcript does not explicitly mention any current or planned fundraising through debt or equity.
- The company has taken an ECB (External Commercial Borrowing) for acquisition-related funding, with the drawdown temporarily parked for future use.
- Debt repayment schedule is outlined, with term loan repayments of approximately Rs. 24 crores in H2 FY24 and Rs. 45-50 crores annually over the next two years, indicating planned debt reduction.
- Management mentioned they have not confirmed any M&A but are always looking for opportunities, suggesting potential future strategic investments.
- No direct indication of fresh equity fundraising was provided during the call.
See what Indoco Remedies management said on order book — free account, 30 seconds.
Capex plans
YesTrack Indoco Remedies — get its next earnings analysis in your feed
How does Indoco Remedies rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Indoco Remedies rank in Pharmaceuticals & Biotechnology?
Compare Indoco Remedies against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Indoco Remedies's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem